X
X
Total 667546 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABA 2009 mouse brain parcel | Brain regions delineated by Dong et al. (2009), with hierarchy established via the NCBO Bioportal ontology (https://bioportal.bioontology.org/ontologies/ABA-AMB). | ILX:0100160 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abacavir | Abacavir (ABC) is the most powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. (Wikipedia) Pharmacology: Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Mechanism of action: Abacavir is a carbocyclic synthetic nucleoside analogue. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-HIV Agents. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Reverse Transcriptase Inhibitors | ILX:0100161 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Abarelix | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. Pharmacology: Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Mechanism of action: Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. Drug type: Approved. Biotech. Investigational. Withdrawn. Drug category: Anti-Testosterone Agents. Antineoplastic Agents | ILX:0100162 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abatacept | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). It is produced through recombinant DNA technology in mammalian cells. The drug has activity as a selective costimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). Pharmacology: Abatacept is the first in a new class of drugs known as Selective Co-stimulation Modulators. Ordinarily, full T-cell activation requires binding of the T-cell receptor to an antigen-MHC complex on the antigen-presenting cell as well as a co-stimulatory signal provided by the binding of the CD28 protein on the surface of the T-cell with the CD80/86 proteins on the surface of the antigen-presenting cell. CTLA4 is a naturally occurring protein which is expressed on the surface of T-cells some hours or days after full T-cell activation and is capable of binding to CD80/86 on antigen-presenting cells with much greater affinity than CD28. Binding of CTLA4-Ig to CD80/86 provides a negative feedback mechanism which results in T-cell deactivation. Abatacept was developed by Bristol-Myers-Squibb and is licensed in the US for the treatment of Rheumatoid Arthritis in the case of inadequate response to anti-TNF-alpha therapy. Mechanism of action: Abatacept is a selective costimulation modulator, shown to inhibit Tcell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis. Drug type: Biotech. Drug category: Antirheumatic Agents | ILX:0100163 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abaxial to | A relational spatial quality in which the bearer entity is away from or on the opposite side of the central axis. | ILX:0100164 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| ABC transporter | ILX:0100165 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Abciximab | Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Pharmacology: Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. Mechanism of action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. Drug type: Approved. Biotech. Investigational. Drug category: Anticoagulants. Antiplatelet Agents | ILX:0100166 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abdominal 10 sensory neuron | ILX:0100167 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Abdominal 9 sensory neuron | ILX:0100168 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Abdominal intersegmental bidendritic neuron isbp | Bipolar multidendritic neuron in the lateral sensory cluster of larval abdominal segments 1-7. Located at the anterior segment boundary, it emits two long dendritic branches along the segment border muscle (muscle 8) (Williams and Shepherd, 1999). | ILX:0100169 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abdominal intersegmental trachea-associated neuron istd | Trachea associated multidendritic neuron located anteriorly in the lateral sensory cluster of larval abdominal segments 1-7. | ILX:0100170 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abdominal neuron | Any neuron (FBbt_00005106) that is part of some abdomen (FBbt_00000020). | ILX:0100171 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abdominal posterior fascicle neuron | Any neuron (FBbt_00005106) that fasciculates with some abdominal segmental nerve (FBbt_00002197). | ILX:0100172 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abducens nerve fibers | Nerve fibers arising from motor neurons in the abducens nucleus that are contained within the pontine tegmentum | ILX:0100173 | 16 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abducens nerve root | ILX:0100174 | 5 | scicrunch | 10/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb | |
| Abducens nucleus | Nucleus located beneath the floor of the 4th ventricle in the pontine tegmentum, containing motor neurons innervating the lateral rectus muscle of the eye (Brodal, Neurological Anatomy, 3rd ed., 1981, pg 533) | ILX:0100175 | 17 | scicrunch | 11/30/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abducens nucleus motor neuron | Motor neuron whose cell soma lies within the abducens nucleus. | ILX:0100176 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Abducens nucleus of ABA 2009 | ILX:0100177 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Abductive reasoning activity | ILX:0100178 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Abductive reasoning function | Abductive reasoning involves applying norms underlying hypothesis generation (http://www.springerreference.com/docs/html/chapterdbid/320173.html). | ILX:0100179 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X